Status:
COMPLETED
Identification of Predictive Gene Expression Profile of Sunitinib Response in Metastatic Clear Cell Renal Carcinomas
Lead Sponsor:
Barretos Cancer Hospital
Conditions:
Kidney Cancer
Biomarkers
Eligibility:
All Genders
18+ years
Brief Summary
Renal cell carcinoma accounts for 2-3% of all cancers in western countries. Brazilian kidney cancer data show an incidence of 6,270 new cases for 2018. New target-molecular therapies have emerged in r...
Eligibility Criteria
Inclusion
- Adult patients
- At least 18 years
- Metastatic clear cell renal carcinoma
- Primary tumors sample of nephrectomy or core biopsy
Exclusion
- insufficient sample for molecular analysis
- Patients with no record of treatment response data
- Patients with a history of previous systemic treatment for Metastatic clear cell renal carcinoma
- Patients with second primary synchronic or metachronic tumor undergoing treatment
- Patients having received less than one cycle of sunitinib in the first line
- Patients have received previous adjuvant and/or neoadjuvant treatment with an interval \< 1 year between the end of treatment and the diagnosis of metastasis.
Key Trial Info
Start Date :
January 2 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 10 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04415697
Start Date
January 2 2019
End Date
April 10 2020
Last Update
June 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Andre Octavio Nicolau Sanches
Barretos, São Paulo, Brazil, 14784400